Evidence map›Paper›PMID 37434027›Full record

ArticlePediatric nephrology (Berlin, Germany)2023

Trajectories of eGFR and risk of albuminuria in youth with type 2 diabetes: results from the TODAY cohort study.

Laure El Ghormli, Hui Wen, Diane Uschner, Morey W Haymond, Kara S Hughan, Katherine Kutney, Lori Laffel, Sherida E Tollefsen, Elia N Escaname, Jane Lynch and 2 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00081328. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00081328 phase3completed

Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial

Ran2004Enrolled699Registered outcomes11Posted comparisons0ConditionsDiabetes Mellitus, Type IIArmsLifestyle Program, Metformin, Rosiglitazone
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Laure El GhormliThe Biostatistics Center, George Washington University, 6110 Executive Boulevard, Suite 750, Rockville, MD, 20852, USA. elghorm@bsc.gwu.edu.ORCID http://orcid.org/0000-0003-4223-8407
Hui WenThe Biostatistics Center, George Washington University, 6110 Executive Boulevard, Suite 750, Rockville, MD, 20852, USA.
Diane UschnerThe Biostatistics Center, George Washington University, 6110 Executive Boulevard, Suite 750, Rockville, MD, 20852, USA.
Morey W HaymondBaylor College of Medicine Children's Nutrition Research Center, Houston, TX, USA.
Kara S HughanUPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA.
Katherine KutneyUH Rainbow Babies and Children's Hospital, Case Western Reserve University, Cleveland, OH, USA.
Lori LaffelJoslin Diabetes Center, Boston, MA, USA.
Sherida E TollefsenDepartment of Pediatrics, Saint Louis University Health Sciences Center, St. Louis, MO, USA.
Elia N EscanameThe University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Jane LynchThe University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Petter BjornstadUniversity of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO, USA.
TODAY Study Group
George Washington University · USThe University of Texas Health Science Center at San Antonio · USChildren's Hospital Colorado · USChildren's Hospital of Pittsburgh · USChildren's Nutrition Research Center at Baylor College of Medicine · USJoslin Diabetes Center · USRainbow Babies & Children's Hospital · USSaint Louis University · US

Funding

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) StudyU01DK061230 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI BRAFFETT, BARBARA HALINA, ZEITLER, PHILIP S. · 2001 to 2019
$231.8M
SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
Management of Pediatric Type 2 Diabetes MellitusU01DK061239 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI KATZ, LORRAINE E LEVITT · 2001 to 2008
$6.9M
Multi-Center Study of the Treatment of T2DM in YouthU01DK061212 · NIDDK · YALE UNIVERSITY · PI CAPRIO, SONIA · 2001 to 2008
$5.3M
Treatment Alternatives in Pediatric Type 2 DiabetesU01DK061242 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI ZEITLER, PHILIP S. · 2001 to 2008
$5.1M
Type 2 Diabetes in Youth: Beta Cell PreservationU01DK061254 · NIDDK · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · PI ARSLANIAN, SILVA A · 2001 to 2007
$4.1M
NIDDK NIH HHS P30 DK036836NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254
6 · The paper itself

Abstract

backgroundWe conducted exploratory analyses to identify distinct trajectories of estimated glomerular filtration rate (eGFR) and their relationship with hyperfiltration, subsequent rapid eGFR decline, and albuminuria in participants with youth-onset type 2 diabetes enrolled in the Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY) study.

methodsAnnual serum creatinine, cystatin C, urine albumin, and creatinine measurements were obtained from 377 participants followed for ≥ 10 years. Albuminuria and eGFR were calculated. Hyperfiltration peak is the greatest eGFR inflection point during follow-up. Latent class modeling was applied to identify distinct eGFR trajectories.

resultsAt baseline, participants' mean age was 14 years, type 2 diabetes duration was 6 months, mean HbA1c was 6%, and mean eGFR was 120 ml/min/1.73 m

conclusionsDistinct eGFR trajectories that associate with albuminuria risk were identified, with the eGFR trajectory characterized by increasing eGFR over time associating with the highest level of albuminuria. These descriptive data support the current recommendations to estimate GFR annually in young persons with type 2 diabetes and provide insight into eGFR-related factors which may contribute to predictive risk strategies for kidney disease therapies in youth with type 2 diabetes.

trial registrationClinicalTrials.gov Identifier: NCT00081328, date registered 2002. A higher resolution version of the Graphical abstract is available as Supplementary information.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesAdolescentAlbuminuriaCohort StudiesDisease ProgressionFemaleFollow-Up StudiesGlomerular Filtration RateHumansRisk FactorsAlbuminuriaDiabetic kidney diseaseGlomerular filtration rateHyperfiltrationTrajectoriesType 2 diabetesYouth

Identifiers

PMID37434027
PMCPMC10875681
OpenAlexW4383896361

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.